PROfound survival with olaparib poised to change practice in prostate cancer
Olaparib, a PARP* inhibitor used to treat ovarian and breast cancer, also extends overall survival (OS) of men with metastatic castration-resistant prostate cancer (mCRPC) harbouring at least one mutation in BRCA1, BRCA2, or ATM, according to final report of the PROfound** study presented at ESMO 2020.